"Cushing Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.
Concept/Terms
Cushing Syndrome- Cushing Syndrome
- Syndrome, Cushing
- Cushing's Syndrome
- Syndrome, Cushing's
- Hypercortisolism
Below are MeSH descriptors whose meaning is more general than "Cushing Syndrome".
Below are MeSH descriptors whose meaning is more specific than "Cushing Syndrome".
This graph shows the total number of publications written about "Cushing Syndrome" by people in Harvard Catalyst Profiles by year, and whether "Cushing Syndrome" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 1 | 3 |
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 2 | 2 |
| 1997 | 2 | 1 | 3 |
| 1998 | 5 | 0 | 5 |
| 1999 | 4 | 2 | 6 |
| 2000 | 8 | 1 | 9 |
| 2001 | 1 | 1 | 2 |
| 2002 | 6 | 2 | 8 |
| 2003 | 3 | 0 | 3 |
| 2004 | 2 | 1 | 3 |
| 2005 | 2 | 2 | 4 |
| 2006 | 2 | 1 | 3 |
| 2007 | 3 | 1 | 4 |
| 2008 | 8 | 1 | 9 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 1 | 3 |
| 2011 | 5 | 3 | 8 |
| 2012 | 5 | 0 | 5 |
| 2013 | 1 | 1 | 2 |
| 2014 | 3 | 0 | 3 |
| 2015 | 4 | 0 | 4 |
| 2016 | 2 | 1 | 3 |
| 2017 | 2 | 0 | 2 |
| 2018 | 5 | 0 | 5 |
| 2019 | 1 | 1 | 2 |
| 2020 | 8 | 0 | 8 |
| 2021 | 6 | 0 | 6 |
| 2022 | 4 | 0 | 4 |
| 2023 | 2 | 0 | 2 |
Below are the most recent publications written about "Cushing Syndrome" by people in Profiles.
-
Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease. Front Endocrinol (Lausanne). 2023; 14:1165681.
-
Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature. Drug Des Devel Ther. 2023; 17:1303-1312.
-
Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes. Eur J Endocrinol. 2022 Dec 01; 187(6):859-871.
-
Outcome of CRH stimulation test and overnight 8 mg dexamethasone suppression test in 469 patients with ACTH-dependent Cushing's syndrome. Front Endocrinol (Lausanne). 2022; 13:955945.
-
Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples. Pituitary. 2022 Dec; 25(6):795-809.
-
[A case of neuralgic amyotrophy with extension disturbance of fingers after Cushing's syndrome remission]. Rinsho Shinkeigaku. 2022 Aug 27; 62(8):632-636.
-
Mislocalization of protein kinase A drives pathology in Cushing's syndrome. Cell Rep. 2022 07 12; 40(2):111073.
-
Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol. 2021 12; 9(12):847-875.
-
Characterization of Outcomes by Surgical Management of Lung Neuroendocrine Tumors Associated With Cushing Syndrome. JAMA Netw Open. 2021 09 01; 4(9):e2124739.
-
Diagnostic Impact of Adrenal Vein Sampling in Adrenal Cushing's Syndrome. J Surg Res. 2021 12; 268:660-666.